EGFR mutational status in penile cancer

Giuseppe Di Lorenzo, Carlo Buonerba, Gabriella Gaudioso, Vincenzo Gigantino, Giuseppe Quarto, Renato De Domenico, Michele Caraglia, Rossella Di Trolio, Paolo A. Ascierto, Sabino De Placido, Sisto Perdonà, Renato Franco

Research output: Contribution to journalArticlepeer-review


Objective: No substantial improvement in overall survival has been obtained over the past two decades in penile cancer (PC). Clinical data are available on the role of epidermal growth factor receptors (EGFR) inhibitors in PC but no EGFR mutational analysis has been conducted. Research design and methods: We reviewed formalin-fixed, paraffin-embedded blocks of PC at the Pathology Department of the National Cancer Institute since 2000 through 2012 to evaluate activating mutations in the tyrosine kinase domain of EGFR: EGFR E746 - A750 specific deletion in exon 19 and EGFR L858R specific point mutation in exon 21. Results: Thirty tumor samples were available for our analysis. EGFR was expressed in all samples at immunohistochemistry. Tested mutations were not identified in any of the samples analyzed. Conclusions: The most frequent activating EGFR mutations detected in non-small setting lung cancer are absent in penile cancer (PC). Sequencing of the entire EGFR gene in patients with PC may provide useful insights, as its mechanism of overexpression and activation in PC remains unknown.

Original languageEnglish
Pages (from-to)501-505
Number of pages5
JournalExpert Opinion on Therapeutic Targets
Issue number5
Publication statusPublished - May 2013


  • Epidermal growth factor receptor expression
  • Epidermal growth factor receptor mutations
  • Immunohistochemistry
  • Penile cancer
  • Tissue micro-array, target therapy

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine


Dive into the research topics of 'EGFR mutational status in penile cancer'. Together they form a unique fingerprint.

Cite this